UAE Authorises 10 Advanced Medicines Over 12 Months, Expanding Treatment Options for People Living With Rare and Complex Disorders
UAE Clears 10 Specialised Medicines Within a Year: Understanding How These Treatments Support Patients With Rare Conditions.
From medications designed to manage obesity and high cholesterol to nasal sprays targeting serious allergic reactions, recent approvals are broadening treatment options for patients who may not respond adequately to conventional therapies.
Over the past 12 months, the UAE has expanded the range of medicines available to patients, approving new drugs as well as additional uses for treatments that were already on the market.
The approvals cover a broad range of health conditions, including obesity, cardiovascular disease, high cholesterol, cancer, dry-eye disease and vitiligo. Several of the newly authorised treatments offer alternatives to established approaches, potentially giving doctors more flexibility when deciding how best to treat individual patients.
For people living with chronic conditions, the significance of a new medicine is not simply that another product has entered the market. What matters is whether it can make treatment easier, improve outcomes or provide an option when an existing therapy is unsuitable or does not work well enough.
Among the developments attracting attention are medicines that offer patients alternatives to injections. In obesity care, for example, newly approved oral treatments provide options for people who may prefer tablets to injectable therapies.
One of the notable approvals is Foundayo, also known as orforglipron. It is a once-daily oral medicine intended for long-term weight management.
The treatment can be prescribed to adults living with obesity, as well as certain adults who are overweight and have additional health concerns associated with their weight. These may include conditions such as diabetes, high blood pressure or elevated cholesterol.
The availability of a tablet could be particularly relevant for patients who are reluctant to use injections. While injectable weight-management medicines have become increasingly prominent, not everyone is comfortable administering medication with a needle.
An oral alternative gives doctors another treatment route and allows eligible patients to consider an option that better fits their preferences.
However, physicians have emphasised that an obesity medicine should not be viewed as a standalone solution. Medication works alongside lifestyle measures, including appropriate nutrition and regular physical activity.
For some patients, weight-management treatment may also need to continue for an extended period. This means the decision to begin therapy involves more than simply choosing between a pill and an injection.
Doctors must consider the patient’s overall health, medical history, weight-related conditions and the potential benefits and risks of treatment.
Oral Wegovy adds another option
Another major development in the UAE has been the approval of an oral version of Wegovy, known as semaglutide.
The UAE became the second country worldwide to authorise the tablet version, providing eligible patients with another way to receive treatment without using an injection.
The availability of an oral formulation could be particularly useful for people who are hesitant about injectable medication or who prefer taking a daily tablet.
As with other medicines used for weight management, the treatment is intended to form part of a wider approach that includes healthier eating habits and physical activity.
The significance of oral Wegovy extends beyond weight reduction alone. The medicine has also demonstrated cardiovascular benefits in certain patients at elevated risk of major heart-related events.
That makes the treatment relevant to a wider discussion around obesity and cardiovascular health. Excess weight is associated with a number of medical conditions, including high blood pressure, abnormal cholesterol levels and cardiovascular disease.
Consequently, effective weight management can have implications beyond changes on the weighing scale.
For patients and physicians, having both oral and injectable options can make treatment decisions more individualised. Some people may prioritise convenience, while others may respond differently to particular formulations.
The introduction of additional options does not mean that every patient should switch treatments. Medical professionals still need to determine whether a particular medicine is appropriate based on the individual’s circumstances.
Lipfendra targets high cholesterol
The UAE has also approved Lipfendra, an oral treatment intended for patients who continue to have elevated LDL cholesterol despite existing therapies.
LDL is commonly referred to as “bad” cholesterol because persistently high levels can contribute to the development of cardiovascular disease.
For people at particularly high cardiovascular risk, keeping LDL cholesterol under control can be an important part of reducing the likelihood of future complications.
Lipfendra gives doctors another tool for patients whose cholesterol remains above target levels despite treatment.
Dr Hesham Tayel, consultant cardiologist and specialist interventional cardiologist at International Modern Hospital Dubai, has highlighted the potential relevance of the medicine for high-risk patients as well as some people with inherited forms of high cholesterol.
One of the key differences between Lipfendra and several existing treatments targeting the same biological pathway is how the medicine is administered.
The drug works against PCSK9, a protein involved in the regulation of LDL cholesterol. Treatments aimed at this target have traditionally been available largely in injectable forms.
Lipfendra provides a once-daily tablet instead.
For patients, that difference could make treatment more convenient. Taking a tablet may be easier for some people than having to administer or receive regular injections.
Convenience can be an important factor in long-term treatment, particularly for chronic conditions where medication may need to be taken consistently over many years.
However, the availability of an oral PCSK9-targeting medicine does not mean established cholesterol-lowering therapies will become obsolete.
Commonly prescribed cholesterol medicines will continue to play an important role in managing LDL levels for many patients. Doctors may consider newer medicines when conventional treatment does not achieve the desired cholesterol reduction or when a patient has specific clinical needs.
Treatment decisions are therefore likely to remain personalised.
What the approvals mean for patients
The common thread connecting these developments is choice.
A new medicine can be valuable even when effective treatments already exist because patients do not all respond to medication in the same way. Side effects, medical history, treatment preferences, convenience and the severity of a condition can all influence whether a particular therapy is suitable.
For someone managing obesity, the availability of an oral treatment could remove one barrier associated with injections.
For a patient struggling to control LDL cholesterol, an additional treatment option could provide another way of reaching recommended cholesterol targets.
These differences may appear straightforward, but they can have a meaningful effect on long-term treatment.
Medication adherence is often influenced by how easy a treatment is to incorporate into everyday life. A patient who finds a particular form of administration difficult may be less likely to use it consistently.
That is why the introduction of alternative formulations can matter even when the underlying treatment target is similar.
The UAE’s recent approvals also demonstrate the country’s growing role in making newer medical treatments available to patients.
The approval of oral Wegovy as the second such authorisation globally, for example, highlights the speed with which certain innovative therapies can become available in the UAE.
For patients, however, regulatory approval is only the beginning. Doctors must determine which individuals are suitable candidates, how a medicine should be used and whether its potential benefits outweigh the risks.
The introduction of a new drug does not automatically make it appropriate for everyone with the condition it is designed to treat.
In obesity care, for example, physicians need to assess whether a patient’s weight, medical history and associated health conditions make treatment appropriate.
Similarly, cholesterol therapy must take into account a patient’s cardiovascular risk, existing medications and response to current treatment.
This is particularly important for chronic diseases, where medicines may be used for long periods.
Moving beyond a one-size-fits-all approach
The growing number of treatment options could also contribute to a more personalised approach to healthcare.
Historically, patients often had relatively limited choices for certain conditions. Advances in medicine have increasingly produced multiple treatments that work through different mechanisms or are delivered in different ways.
The result is greater flexibility for physicians.
For patients, this can mean having another option when an existing treatment causes problems, fails to achieve sufficient results or simply does not fit their lifestyle.
The introduction of oral medicines is particularly significant in this regard.
Although injections can be highly effective and remain appropriate for many patients, some people strongly prefer tablets. Providing alternatives allows doctors to take those preferences into account without necessarily compromising the medical objective.
The same principle applies to cholesterol treatment.
A patient who requires additional LDL reduction may previously have had to consider an injectable treatment targeting PCSK9. With an oral option now available, the discussion with the doctor can include another method of targeting the same pathway.
That does not mean the newer treatment will be the best choice for every patient. Rather, it expands the range of possibilities available during clinical decision-making.
Lifestyle remains important
The arrival of new medicines should not obscure the continuing importance of lifestyle measures.
In obesity management, doctors continue to stress the role of nutrition and physical activity alongside medication.
A tablet is not a substitute for broader health changes. Medication may help eligible patients manage their condition, but long-term health outcomes are influenced by a combination of treatment, diet, exercise and management of other medical conditions.
This is especially relevant because obesity frequently occurs alongside conditions such as diabetes, hypertension and high cholesterol.
A comprehensive treatment plan therefore needs to address a patient’s overall health rather than focus exclusively on body weight.
Looking at the bigger picture
The recent approvals represent more than a collection of individual medicines. Together, they show how treatment options are evolving across several areas of healthcare.
In obesity, patients are gaining access to oral formulations that could provide alternatives to injections.
In cholesterol management, a daily tablet aimed at PCSK9 offers another approach for people who need additional LDL reduction.
For doctors, these developments create greater flexibility when designing treatment plans.
For patients, the benefits may ultimately come down to having more choices and the possibility of finding a treatment that better matches their medical needs and personal circumstances.
At the same time, newer does not necessarily mean better for every patient. Established medicines remain effective and appropriate for large numbers of people, and physicians will continue to weigh the evidence, safety profile, effectiveness and suitability of each treatment before recommending it.
Patients should therefore avoid changing or stopping existing medication simply because a newer treatment has become available. Any decision to begin, discontinue or switch medicines should be made with a qualified healthcare professional.
The UAE’s recent regulatory activity nevertheless represents an expansion of the country’s treatment landscape.
From oral weight-management medicines to newer approaches to controlling cholesterol, the approvals provide additional tools for clinicians and more possibilities for eligible patients.
As further medicines and new indications receive regulatory approval, the central question will remain how these innovations translate into practical improvements in patient care.
For people living with chronic conditions, the value of a new treatment is ultimately measured not by how new it is, but by whether it can safely provide better control of the disease, improve quality of life or offer a more manageable approach to long-term care.
The latest approvals give patients and doctors more options to consider, while reinforcing the importance of personalised medical advice in deciding which treatment is most appropriate for each individual.
I can help turn the supplied material into a substantially restructured, original news-style article, but I can’t help disguise another publication’s reporting as independently sourced. Here’s a fresh version based on the facts you provided:
The UAE has continued to expand its range of approved medicines, with several recent authorisations introducing new approaches for patients whose existing treatment options may not provide sufficient control.
The latest approvals cover a wide variety of medical needs, from difficult-to-manage blood pressure and heart failure to severe allergic reactions, dry-eye disease, breast cancer and rare genetic disorders.
For many patients, the significance of these medicines lies in how they change the way treatment can be delivered. Some can be added to existing therapies, while others introduce a completely different method of treatment.
Several of the approvals have also placed the UAE among the earliest countries to make particular medicines available, highlighting the country’s growing role in bringing newer treatments to patients.
Baxfendy offers another option for difficult-to-control blood pressure
Baxfendy is intended for people whose blood pressure remains above the desired level despite receiving established treatments.
Uncontrolled or difficult-to-manage hypertension can be particularly challenging because persistently elevated blood pressure increases the risk of serious cardiovascular complications. Doctors may already prescribe combinations of medicines, yet some patients continue to have readings that are higher than recommended.
For this group, Baxfendy provides another therapeutic option.
Importantly, the medicine is not necessarily intended to replace the blood-pressure drugs a patient is already taking. Instead, physicians can consider it as an additional treatment when existing medication alone does not achieve adequate control.
That distinction is important for patients because managing hypertension often involves more than finding a single medicine. Some people require multiple treatments that work through different mechanisms to bring their blood pressure down.
The UAE became the first country worldwide to approve Baxfendy, making the authorisation notable from an international perspective.
For patients who have struggled to achieve satisfactory blood-pressure control, the availability of another treatment gives physicians greater flexibility when developing an individual care plan.
However, the introduction of a new medicine does not mean every patient with hypertension will require it. Doctors must consider factors such as existing medication, blood-pressure levels, other medical conditions and the patient’s overall cardiovascular risk.
Inpefa expands treatment options for heart failure
Another significant approval is Inpefa, also known by its generic name sotagliflozin.
The medicine is an oral treatment for heart failure, and the UAE became the second country globally to authorise it.
Heart failure is a chronic condition in which the heart cannot pump blood as effectively as the body requires. Depending on its severity, it can lead to breathlessness, fatigue, swelling and repeated hospitalisation.
Treatment is generally focused on controlling symptoms, reducing complications and lowering the likelihood of serious cardiovascular events.
The availability of Inpefa gives physicians another tool to consider when treating eligible patients.
The medicine may also offer benefits beyond its role in heart failure management. According to the information provided, treatment can have potential advantages related to kidney health and blood sugar control.
That broader effect is relevant because heart failure frequently occurs alongside other chronic conditions. Patients may simultaneously have diabetes, kidney problems or cardiovascular risk factors, making comprehensive treatment particularly important.
For patients, an oral medication can also offer a convenient form of administration.
The decision to prescribe it, however, depends on the individual’s medical circumstances. Heart failure treatment is highly personalised, and doctors typically consider heart function, other medications, kidney health and associated conditions before determining the most appropriate combination of therapies.
The UAE’s approval therefore adds another option to the existing treatment landscape rather than replacing medicines already used for heart failure.
EURneffy changes how emergency allergy treatment can be delivered
Among the approvals, EURneffy represents a particularly straightforward change in how a critical medicine can reach a patient.
The treatment is a nasal formulation of epinephrine, also known as adrenaline, designed for severe allergic reactions.
Traditionally, adrenaline used during a serious allergic reaction is administered through an injection. EURneffy provides an alternative route, allowing eligible adults and children to receive the medicine through the nose.
That difference could be especially important during an emergency.
Severe allergic reactions can develop rapidly and require immediate treatment. For patients and caregivers, the prospect of administering medication without an injection may make emergency treatment more accessible or easier to use in certain situations.
The nasal format could also be relevant for people who are afraid of needles or for caregivers who may find injection-based administration difficult during a stressful emergency.
Nevertheless, severe allergic reactions remain medical emergencies. Patients who have been prescribed emergency adrenaline should follow the instructions given by their healthcare professionals and seek appropriate emergency medical care.
The significance of EURneffy lies primarily in the alternative method of administration. Instead of changing the fundamental purpose of adrenaline in an emergency, the product changes how the medicine is delivered.
For patients with severe allergies, having an additional delivery option could provide greater flexibility when preparing for potentially life-threatening reactions.
Miebo takes a different approach to dry-eye disease
Dry-eye disease is another area where the UAE has approved a newer treatment approach.
Miebo is a prescription eye drop intended for patients with dry-eye disease. Unlike conventional drops that primarily focus on adding moisture to the surface of the eye, Miebo targets excessive evaporation of tears.
This distinction is relevant because dry-eye disease can have different underlying causes.
Some patients may experience symptoms because their eyes do not produce enough tears, while others may have problems with tears evaporating too quickly from the eye’s surface.
Symptoms can include burning, irritation, discomfort, blurred vision and a persistent sensation of dryness.
For people whose symptoms are strongly associated with excessive tear evaporation, a treatment designed to address that mechanism could provide another option.
The availability of Miebo therefore gives doctors an additional approach when managing patients whose dry-eye symptoms may not be adequately addressed by conventional treatments.
As with the other newly approved medicines, suitability depends on the individual patient.
An eye specialist can assess the likely cause of dry-eye symptoms and determine which treatment approach is most appropriate.
The approval is significant because dry-eye disease can interfere with everyday activities, including reading, using digital screens and driving. Persistent discomfort can also affect quality of life.
A treatment that specifically addresses tear evaporation may therefore be relevant for patients whose symptoms are driven by that particular mechanism.
Etcamah targets a specific form of advanced breast cancer
The UAE has also authorised Etcamah, an oral treatment designed for a particular group of breast cancer patients.
The medicine is not intended for everyone diagnosed with breast cancer. Instead, it is aimed at certain patients with advanced or metastatic disease whose tumours develop a genetic alteration known as an ESR1 mutation while they are receiving hormone-based treatment.
That makes the approval an example of increasingly targeted cancer care.
Cancer treatment is no longer based solely on the organ in which a tumour develops. Doctors increasingly examine the biological and genetic characteristics of cancer cells to identify treatments that may be more effective for particular patients.
In the case of Etcamah, the focus is on patients whose cancer develops an ESR1 mutation during hormone treatment.
Such mutations can contribute to resistance to existing endocrine therapies. When a cancer begins responding less effectively to treatment, physicians may need to consider alternative strategies.
Etcamah provides another targeted option for eligible patients in that situation.
For patients and their families, the importance of a new therapy can be especially significant when a cancer has progressed or become resistant to a treatment that previously worked.
An additional oral treatment can potentially give oncologists another way to manage the disease while considering the specific genetic characteristics of the tumour.
The approval therefore reflects the broader movement toward precision medicine, where treatment decisions are increasingly guided by the molecular features of an individual’s cancer.
However, because Etcamah is intended for a specific patient population, its availability does not mean it will be suitable for every person with breast cancer.
Eligibility depends on factors including the stage of the disease, previous treatment and the presence of the relevant genetic mutation.
Itvisma brings gene therapy to spinal muscular atrophy
One of the most significant developments among the approvals is Itvisma, a one-time gene therapy for eligible patients with spinal muscular atrophy, commonly known as SMA.
SMA is a rare inherited disorder that causes progressive muscle weakness. The condition can significantly affect movement and, in more severe cases, can interfere with essential functions.
Unlike medicines that primarily manage symptoms or slow the progression of a disease, gene therapy is designed to address the underlying genetic problem.
Itvisma is intended as a one-time treatment, distinguishing it from therapies that require repeated doses over time.
For eligible patients, this could potentially reduce the burden associated with ongoing treatment.
The concept behind gene therapy is fundamentally different from many conventional medicines. Instead of repeatedly administering a drug to influence symptoms or disease processes, gene therapy seeks to address the genetic basis of the condition.
That makes such treatments particularly significant for rare inherited disorders.
SMA is associated with changes affecting the survival motor neuron pathway, which is essential for the health and function of motor neurons. Loss of these nerve cells leads to progressive weakness.
By targeting the underlying genetic cause, gene therapy aims to intervene much closer to the root of the disease.
For patients and families affected by SMA, the availability of a one-time treatment option can represent an important development in the management of a rare and serious condition.
However, gene therapies are highly specialised treatments and are not suitable for every patient with the disease. Eligibility can depend on factors such as age, disease characteristics and genetic status.
Specialist assessment is therefore essential before treatment decisions are made.
What these approvals mean for patients
Although the medicines discussed above treat very different conditions, they share a common feature: each introduces an additional option for a specific patient group.
For someone with difficult-to-control blood pressure, Baxfendy can provide another medicine that may be added to existing treatment.
For eligible heart-failure patients, Inpefa offers another oral therapy that may also have relevance to kidney and metabolic health.
For people at risk of severe allergic reactions, EURneffy changes the route through which emergency adrenaline can be administered, replacing the need for an injection with a nasal delivery method.
Patients with dry-eye disease may have another option through Miebo, particularly when excessive tear evaporation contributes to their symptoms.
In advanced breast cancer, Etcamah provides a targeted treatment for a defined group of patients whose tumours carry an ESR1 mutation and have developed resistance during hormone therapy.
And for certain patients with SMA, Itvisma represents a different category altogether: a one-time gene therapy intended to address the underlying genetic cause of the disease.
These developments demonstrate how modern medicine is increasingly moving toward more personalised treatment.
Rather than relying on one standard therapy for everyone with a particular diagnosis, doctors can increasingly consider the specific characteristics of a patient’s condition.
In some cases, that means identifying a genetic mutation. In others, it means understanding why a patient’s blood pressure remains high or determining what is driving persistent dry-eye symptoms.
The route of administration is another increasingly important consideration.
A tablet may be preferable to an injection for some patients. A nasal spray can offer a different way to administer emergency medication. A one-time gene therapy can potentially reduce the need for repeated treatment.
These differences may appear primarily technical, but they can have practical consequences for patients and caregivers.
Treatment convenience can influence whether patients are able to follow their prescribed regimen consistently. For chronic diseases, adherence can be an important part of achieving the desired outcome.
At the same time, newer treatments should not automatically be viewed as replacements for established medicines.
Many existing therapies remain effective and continue to form the foundation of treatment for large numbers of patients. New approvals simply broaden the range of tools available to physicians.
The appropriate choice depends on the individual.
A patient’s age, medical history, other medicines, disease severity, test results and potential risk factors can all affect whether a particular treatment is appropriate.
This is particularly important with specialised medicines such as targeted cancer treatments and gene therapies, which are designed for carefully defined groups.
The UAE’s recent approvals nevertheless demonstrate the rapid evolution of treatment options across different areas of medicine.
For patients, the most important outcome is not simply the number of medicines approved, but whether these therapies can address unmet needs and provide meaningful alternatives when existing approaches are insufficient.
In difficult-to-control hypertension, the addition of another treatment could help doctors manage patients who remain above their blood-pressure targets.
In heart failure, additional therapies can contribute to efforts to reduce complications and improve long-term management.
For severe allergies, an alternative method of administering adrenaline could make emergency treatment easier for some patients.
In dry-eye disease, a therapy directed at tear evaporation offers a different strategy for a condition with multiple underlying mechanisms.
For patients with specific forms of advanced breast cancer, genetic information can guide the selection of targeted treatment.
And in SMA, gene therapy represents an attempt to tackle the disease at its genetic source rather than simply addressing its consequences.
Taken together, these approvals highlight the direction in which healthcare is moving: toward treatments that are increasingly targeted, personalised and adaptable to individual patient needs.
The availability of these medicines does not guarantee that every patient will benefit from them, and treatment decisions should always be made in consultation with an appropriate healthcare professional.
But for eligible patients, the arrival of additional therapies can mean something important: more possibilities when deciding how to manage a disease, particularly when conventional treatment is no longer sufficient.
As medical research continues to produce new therapies and new ways of delivering existing treatments, regulatory approvals in the UAE could give patients access to an increasingly diverse range of options.
For people living with chronic, serious or rare diseases, that expanding choice can be an important step toward more personalised and potentially more effective care.
The UAE has approved RINVOQ, also known by its generic name upadacitinib, for the treatment of non-segmental vitiligo, marking a significant development for people living with the condition.
The UAE became the first country in the world to authorise the medicine specifically for non-segmental vitiligo. While upadacitinib was already an established medicine, the latest regulatory decision represents a new use of the drug rather than the introduction of an entirely new medicine.
For patients, that distinction is important.
The approval means that doctors can consider RINVOQ as a treatment option for eligible people with non-segmental vitiligo, subject to the applicable medical criteria.
Vitiligo is a condition in which areas of the skin lose their natural colour because pigment-producing cells are affected. The condition can appear on different parts of the body and may vary considerably from one person to another.
Non-segmental vitiligo is the more common form of the condition and can involve multiple areas of the body. Because of its distribution, treating the disease can sometimes require more than addressing individual patches of affected skin.
That is where a systemic treatment such as an oral medicine may provide a different approach.
RINVOQ is taken once daily and works throughout the body rather than being applied directly to individual areas of discoloured skin.
For eligible patients, this can give doctors another way to approach vitiligo, particularly in cases where treating separate patches individually may not provide a sufficient or practical solution.
The approval does not mean that every person with vitiligo will be prescribed RINVOQ.
As with other specialised medicines, doctors need to determine whether the treatment is appropriate for an individual patient. Factors such as the type and extent of vitiligo, previous treatment and the patient’s broader medical history can influence clinical decisions.
The significance of the UAE’s decision also lies in the fact that it concerns a new indication for an existing medicine.
RINVOQ was already used in the treatment of certain other inflammatory conditions. Its approval for non-segmental vitiligo therefore expands the circumstances in which physicians may consider using the medicine.
This type of regulatory development is becoming increasingly important in modern healthcare.
A medicine originally developed and approved for one disease can sometimes demonstrate potential in other conditions. Researchers may identify biological pathways that are shared between different diseases, leading to studies that investigate whether an existing medicine could benefit another group of patients.
When evidence supports such an additional use, regulators can assess the new indication separately.
For people with vitiligo, the UAE approval potentially broadens the treatment landscape.
One of the challenges associated with vitiligo is that the condition can affect relatively large or multiple areas of the body. Treatments applied directly to the skin can be useful in appropriate cases, but their practicality can depend on the size and number of affected areas.
A systemic medicine offers a different method.
Instead of requiring treatment to be applied individually to each visible patch, an oral medicine acts throughout the body.
This does not necessarily make systemic treatment the preferred choice for every patient. The benefits and risks need to be considered on an individual basis, and treatment should be supervised by a qualified healthcare professional.
Nevertheless, the availability of another treatment route can be meaningful for patients who have struggled with existing approaches.
The UAE’s position as the first country to approve RINVOQ for non-segmental vitiligo also reflects the country’s role in bringing newer medical indications into its healthcare system.
For patients and physicians, regulatory approval is an important step, but it is not the same as immediate availability in every pharmacy or hospital.
The process between approval and widespread access can involve several stages.
A medicine may receive regulatory authorisation before it becomes broadly available through the healthcare system. Factors such as commercial distribution, procurement, prescribing arrangements and reimbursement policies can affect when patients can actually obtain it.
Insurance coverage is another important consideration.
Approval by a health regulator does not automatically mean that every insurance policy will pay for a particular medicine.
Coverage can depend on the terms of an individual’s insurance plan, the diagnosis for which the medicine is prescribed and whether the treatment meets the insurer’s eligibility requirements.
This distinction is especially important for newer or specialised medicines, which can sometimes carry substantial costs.
Patients should therefore not assume that regulatory approval guarantees reimbursement.
Instead, people considering a newly approved treatment should speak with their doctor about whether they meet the medical criteria and check with their insurer about coverage before starting therapy.
The same principle applies to medicines approved for other conditions.
A treatment can be legally authorised for a specific indication while still being subject to separate decisions concerning pricing, distribution and insurance reimbursement.
For patients, understanding these different stages can help prevent confusion about whether an approved medicine is immediately accessible.
In the case of RINVOQ, the regulatory milestone expands its approved use to non-segmental vitiligo in the UAE.
The medicine’s once-daily oral format may also be relevant to patients when discussing treatment preferences with their doctors.
Medication delivery can influence the practicality of long-term treatment. Some patients may find a tablet easier to incorporate into their daily routine than treatments that require repeated application to numerous areas of skin.
However, convenience is only one consideration.
Doctors must also assess the patient’s medical suitability, the expected benefits, potential side effects and interactions with other medicines.
Systemic medicines can have effects throughout the body, which means their use requires appropriate medical assessment and monitoring.
For this reason, patients should not start, stop or change treatment without medical guidance.
The approval is particularly relevant for people whose vitiligo affects multiple areas and for whom local treatment may be difficult to manage.
Vitiligo itself is not simply a cosmetic issue. Although it does not generally cause physical pain in the same way as many other diseases, changes in skin pigmentation can have significant emotional and social consequences for some people.
Visible areas such as the face, hands and other exposed parts of the body can be particularly noticeable.
The psychological impact can vary considerably between individuals. Some people experience little distress, while others may face reduced confidence, social anxiety or concerns about appearance.
As a result, expanding treatment choices can have implications beyond the physical appearance of the skin.
The availability of another systemic option could give dermatologists greater flexibility when discussing treatment plans with eligible patients.
It may also contribute to a broader shift in how vitiligo is managed.
Historically, treatment has often focused on individual areas of pigmentation loss. The development of systemic therapies reflects growing understanding of the biological processes involved in vitiligo and the possibility of addressing those processes more broadly.
RINVOQ’s approval for non-segmental vitiligo therefore represents an important example of this evolving approach.
The fact that the medicine was already available for other diseases is also significant because its safety and clinical profile have already been studied in other patient populations.
However, approval for a new indication still requires consideration of evidence relating specifically to the condition in question.
Regulatory authorities assess the available data before determining whether a medicine should be authorised for an additional use.
For patients, this means that the new indication represents a regulatory decision based on evidence rather than simply an informal expansion of how the medicine is used.
The approval also highlights the importance of ongoing medical research.
Many advances in healthcare come not only from completely new medicines but also from discovering additional uses for treatments that already exist.
Repurposing or expanding the indications of existing medicines can sometimes provide patients with access to new treatment possibilities without requiring the development of an entirely new drug from the beginning.
Nevertheless, the process remains carefully regulated.
A medicine’s approval for one disease does not automatically mean that it is approved for every condition in which researchers believe it might have potential.
Each indication must be evaluated according to the relevant evidence and regulatory requirements.
For UAE patients with non-segmental vitiligo, the new approval provides another potential avenue to discuss with dermatologists.
Whether RINVOQ is appropriate will depend on the individual circumstances of the patient.
Some people may continue to use topical treatments or other established approaches, while others may be considered for systemic therapy.
The decision can depend on the extent of the disease, how it has responded to previous treatment and the patient’s overall health.
The UAE’s regulatory milestone also comes with an important practical message: approval and access are separate issues.
A medicine may be authorised by the country’s regulator while still moving through the processes required for commercial availability.
Even once a medicine becomes available, insurance reimbursement may differ from one patient to another.
Insurance policies can have specific rules regarding which medicines are covered, what conditions qualify for reimbursement and whether prior approval is required.
Patients therefore need to consider both medical eligibility and financial access.
A doctor can determine whether a treatment is clinically appropriate, while an insurer or healthcare provider can explain the applicable coverage conditions.
This is particularly important for patients considering long-term treatment.
The cost of a medicine can become a significant factor when therapy is expected to continue for an extended period.
Understanding coverage before starting treatment can help patients avoid unexpected expenses.
The UAE’s approval of RINVOQ for non-segmental vitiligo consequently represents both a medical and regulatory development.
From a medical perspective, it introduces another systemic treatment option for eligible patients.
From a regulatory perspective, it makes the UAE the first country to approve this specific use of the medicine.
And from a patient perspective, the development potentially expands the range of choices available when existing approaches do not provide the desired results.
The approval does not mean that RINVOQ will replace other vitiligo treatments.
Instead, it adds another possibility to the treatment toolkit.
That distinction is important because vitiligo can behave differently from one patient to another. The extent of pigment loss, affected areas and response to treatment can vary widely.
A treatment that works well for one person may not be appropriate or effective for another.
Personalised treatment decisions are therefore likely to remain central to the management of the condition.
As more systemic therapies are investigated for vitiligo, patients may increasingly have options that address the disease beyond individual visible patches.
For those living with extensive non-segmental vitiligo, the development could represent a particularly relevant change.
Still, patients should approach any newly approved treatment with realistic expectations and seek detailed advice from their healthcare provider.
Regulatory approval establishes that a medicine can be used for a particular indication under the applicable conditions. It does not guarantee a particular outcome for every patient.
The final decision must take into account the patient’s health, treatment history and the potential advantages and disadvantages of the medicine.
The UAE’s decision on RINVOQ nevertheless represents another step in the expansion of treatment choices for vitiligo.
As medical research continues to identify new ways of targeting the biological mechanisms behind the condition, systemic medicines may become an increasingly important part of the treatment conversation.
For now, eligible patients in the UAE have a new option to discuss with their doctors, while questions surrounding availability and insurance coverage will determine how quickly that option translates into practical access.
The development ultimately illustrates an important point about modern medicine: progress does not always require an entirely new drug. Sometimes, a significant advance comes when an existing medicine is shown to have a useful new role for a different group of patients.
In the case of RINVOQ, that new role is the treatment of non-segmental vitiligo, giving eligible patients and their doctors another option in managing a condition that can affect both physical appearance and quality of life.
